The anemia that is common in end-stage renal disease (ESRD) patients who receive hemodialysis is typically due to a lack of erythropoietin [12,18,19], whose replacement raises persistent challenges in the balancing of end-stage CDK patients [2,20]. This evidence concerns the gene EPO and anemia (phenotype).